Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules by Das, Undurti N
BioMed  Central
Page 1 of 18
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Hypothesis
Essential fatty acids and their metabolites could function as 
endogenous HMG-CoA reductase and ACE enzyme inhibitors, 
anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, 
anti-inflammatory, cytoprotective, and cardioprotective molecules
Undurti N Das1,2
Address: 1UND Life Sciences, 13800 Fairhill Road, #321, Shaker Heights, OH 44120, USA and 2Department of Medicine, Bharati Vidyapeeth 
University Medical College, Pune, India
Email: Undurti N Das - undurti@hotmail.com
Abstract
Lowering plasma low density lipoprotein-cholesterol (LDL-C), blood pressure, homocysteine, and
preventing platelet aggregation using a combination of a statin, three blood pressure lowering drugs
such as a thiazide, a β blocker, and an angiotensin converting enzyme (ACE) inhibitor each at half
standard dose; folic acid; and aspirin-called as polypill- was estimated to reduce cardiovascular
events by ~80%. Essential fatty acids (EFAs) and their long-chain metabolites: γ-linolenic acid (GLA),
dihomo-GLA (DGLA), arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid
(DHA) and other products such as prostaglandins E1 (PGE1), prostacyclin (PGI2), PGI3, lipoxins
(LXs), resolvins, protectins including neuroprotectin D1 (NPD1) prevent platelet aggregation, lower
blood pressure, have anti-arrhythmic action, reduce LDL-C, ameliorate the adverse actions of
homocysteine, show anti-inflammatory actions, activate telomerase, and have cytoprotective
properties. Thus, EFAs and their metabolites show all the classic actions expected of the "polypill".
Unlike the proposed "polypill", EFAs are endogenous molecules present in almost all tissues, have
no significant or few side effects, can be taken orally for long periods of time even by pregnant
women, lactating mothers, and infants, children, and adults; and have been known to reduce the
incidence cardiovascular diseases including stroke. In addition, various EFAs and their long-chain
metabolites not only enhance nitric oxide generation but also react with nitric oxide to yield their
respective nitroalkene derivatives that produce vascular relaxation, inhibit neutrophil degranulation
and superoxide formation, inhibit platelet activation, and possess PPAR-γ ligand activity and release
NO, thus prevent platelet aggregation, thrombus formation, atherosclerosis, and cardiovascular
diseases. Based on these evidences, I propose that a rational combination of ω-3 and ω-6 fatty acids
and the co-factors that are necessary for their appropriate action/metabolism is as beneficial as that
of the combined use of a statin, thiazide, a β blocker, and an angiotensin converting enzyme (ACE)
inhibitor, folic acid, and aspirin. Furthermore, appropriate combination of ω-3 and ω-6 fatty acids
may even show additional benefits in the form of protection from depression, schizophrenia,
Alzheimer's disease, and enhances cognitive function; and serve as endogenous anti-inflammatory
molecules; and could be administered from childhood for life long.
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Introduction
Cardiovascular diseases (CVD) are responsible for signifi-
cant morbidity and mortality throughout the world. Stud-
ies revealed that smoking cessation, β-blockers, anti-
platelet agents, angiotensin converting enzyme (ACE)
inhibitors, and lipid lowering agents such as statins, each
reduce the risk of vascular events to a moderate but impor-
tant degree [1-9]. In addition, observational studies sug-
gested lower rates of fractures and dementia with statins,
and lower rates of cataracts with anti-oxidant vitamins,
though these observations need to be confirmed by ran-
domised trials [9]. The results of the MRC/BHF-HPS study
led to the suggestion that using a combination of aspirin,
β-blockers, statins, and ACE inhibitors could prevent
about two-thirds to three-quarters of future vascular
events [10]. It was suggested that a combination pill
(called as "polypill") consisting of atorvastatin 10 mg or
simvastatin 40 mg; three blood pressure lowering drugs
such as a thiazide, a β-blocker, and an ACE inhibitor, each
at half standard dose; folic acid 0.8 mg; and aspirin 75 mg
could reduce coronary heart disease (CHD) events by
88% (95% confidence interval 84% to 91%) and stroke
by 80% (71% to 87%), and if such a combination pill is
taken from age 55 years of age, at least one third of people
taking it, would on an average add about 11 years of life
free from an CHD event or stroke [11].
Further support to the concept of polypill for the preven-
tion of primary and secondary cardiovascular diseases
proposed by Wald and Law [11] is provided by the work
of Hippisley-Cox and Coupland [12] who examined the
individual and combined effects of three of the polypill
ingredients-statins, aspirin, and blood pressure lowering
drugs. Their analysis of 11330 patients with CHD showed
that all cause mortality is lower in those taking two or
three drugs compared with those taking single agents.
These findings are consistent with previous studies
[13,14] that showed that a combination of two drugs-
aspirin and statin-is superior to either drug alone in the
secondary prevention of CHD. However, it was also noted
that synergistic effects are seen with two, but not three or
four, drug combinations in secondary prevention of CHD.
But concerns have been raised about the adverse effects of
such a polypill. For instance, β blockers are unsuitable for
subjects with bronchial asthma, and some are intolerant
to aspirin and develop significant gastrointestinal side
effects. It may be necessary to closely monitor to detect
serious adverse effects of statins, and renal failure due to
ACE inhibitors and angiotensin-II receptor antagonists.
Furthermore, the efficacy of aspirin in men is established
[15], but its efficacy in women is not certain [16]. A recent
study showed that 2.5 mg of folic acid (the proposed poly-
pill dosage is 0.8 mg/day) was not associated with a reduc-
tion in stroke, coronary events, and death in patients who
previously had a cerebral infarction despite a moderate
reduction of total homocysteine during the 2 years of fol-
low-up [17]. Another major concern about the primary
prevention strategy of the "polypill" is related to the pos-
sibility that it might lead to medicalising of the popula-
tion since, it is highly cost effective to treat individuals at
high risk compared to those at lower risk that is much
more expensive to treat in terms of gain in quality
adjusted life years. Hence, it will be worthwhile to look for
alternatives to "polypill" that is less expensive, more
acceptable, less likely to cause side effects and does not
lead to medicalising the population. I propose that a
rational combination of ω-3 and ω-6 fatty acids may, in
fact, be more beneficial compared to the "polypill" in the
primary and secondary prevention of cardiovascular dis-
eases.
Metabolism of essential fatty acids
Essential fatty acids (EFAs) are essential for survival and
they cannot be synthesized in the body and hence, have to
be obtained in our diet and thus, are essential [18-21].
There are two types of naturally occurring EFAs in the
body, the ω-6 series derived from linoleic acid (LA, 18:2)
and the ω-3 series derived from α-linolenic acid (ALA,
18:3). Both ω-6 and ω-3 series are metabolized by the
same set of enzymes to their respective long-chain metab-
olites. While some of the functions of EFAs require their
conversion to eicosanoids and other products, in majority
of the instances the fatty acids themselves are active.
LA is converted to γ-linolenic acid (GLA, 18:3, n-6) by the
action of the enzyme Δ6 desaturase (d-6-d) and GLA is
elongated to form dihomo-GLA (DGLA, 20:3, n-6), the
precursor of the 1 series of prostaglandins (PGs). DGLA
can also be converted to arachidonic acid (AA, 20:4, n-6)
by the action of the enzyme Δ5 desaturase (d-5-d). AA
forms the precursor of 2 series of prostaglandins, throm-
boxanes and the 4 series of leukotrienes. ALA is converted
to eicosapentaenoic acid (EPA, 20:5, n-3) by d-6-d and d-
5-d. EPA forms the precursor of the 3 series of prostaglan-
dins and the 5 series of leukotrienes (see Figure 1 for the
metabolism of EFAs). AA and EPA give rise to their respec-
tive hydroxy acids, which, in turn, are converted to respec-
tive leukotrienes (LTs). In addition, AA, EPA, and DHA
form precursor to anti-inflammatory compounds lipox-
ins, resolvins, and protectins (neuroprotectin D1 is one
such compound derived from DHA) [22-27]. PGs, LTs,
lipoxins (LXs), and resolvins are highly active, modulate
inflammation, and are involved in several physiological
and pathological processes [18]. In general, the term
"EFAs" is used to refer to all unsaturated fatty acids: LA,
GLA, DGLA, AA, ALA, EPA, and DHA; and the term poly-
unsaturated fatty acids (PUFAs) refer to GLA, DGLA, AA,
EPA, and DHA. Although the terms EFAs and PUFAs are
used interchangeably, it should be understood that allLipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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Metabolism of essential fatty acids Figure 1
Metabolism of essential fatty acids. Prostaglandins of 3 series are less pro-inflammatory compared to prostaglandins of 2 
series. Resolvins are formed from both EPA and DHA and are known to have anti-inflammatory actions and participate in the 
resolution of inflammation. EPA can be converted to DHA. DHA can be retroconverted to EPA. It is estimated that about 30–
40% of DHA can be retroconverted to EPA. The biochemical and/or clinical significance of this retroconversion of DHA to 
EPA are not known. ____ Indicates beneficial action in the form of increase in the synthesis, action, or remission of disease 
process. ____ Indicates decrease in the synthesis, action or enhancement of pathological process. ____ Indicates inhibition of 
HMG-CoA and ACE enzymes by PUFAs/EFAs.
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EFAs are PUFAs but all PUFAs are not EFAs. Only LA and
ALA qualify to be EFAs; whereas GLA, DGLA, AA, EPA, and
DHA are PUFAs. On the other hand, LA, GLA, DGLA, AA,
ALA, EPA, and DHA are also called as LCPUFAs (long-
chain polyunsaturated fatty acids). Many of the functions
of EFAs are also brought about by PUFAs and EFA-defi-
ciency states can be corrected to a large extent by PUFAs
that suggests that PUFAs are "functional EFAs". Hence, in
general, many authors use the terms EFAs and PUFAs
interchangeably. This convention is followed in the
present discussion.
Dietary sources of EFAs
EFAs: LA and ALA are present in human diet in abundant
amounts and hence, EFA-deficiency is uncommon. In cer-
tain specific conditions such as total parenteral nutrition
(TPN) and severe malabsorption occasionally EFA defi-
ciency could be seen. The present TPN solutions contain
adequate amounts of EFAs. The manifestations of EFA
deficiency include: dry and scaly skin, hepatospleenome-
galy, immunodeficiency, inappropriate water loss
through the skin, dehydration, scalp dermatitis, alopecia,
and depigmentation of hair. EFAs are widely distributed
in normal human diet. The main dietary sources of EFAs
are as follows.
Human breast milk is rich in all types of PUFAs [18] that
explains why breast-fed children are healthier compared
to bottle-fed. LA and ALA are present in significant
amounts in dairy products, organ meats such as liver, and
many vegetable oils such as sunflower, safflower, corn
and soy. GLA is present in evening primrose oil at concen-
trations of 7–14% of total fatty acids; in borage seed oil it
is 20–27%; and in black currant seed oil at 15–20%. GLA
is also found in some fungal sources [18]. DGLA is found
in liver, testes, adrenals, and kidneys. AA is present in
meat, egg yolks, some seaweeds, and some shrimps. Aver-
age daily intake of AA is estimated to be ~100–200 mg/
day that accounts for the total daily production of various
PGs. EPA and DHA are present mainly in marine fish.
Cow's milk contains very small amounts of GLA, DGLA
and AA.
EFAs/PUFAs are unstable due to the presence of 2 or more
double bonds in their structure. Substantial loss of EFAs/
PUFAs occurs during food processing and hydrogenation
of oils. Exposure to high temperatures and hydrogenation
process causes denaturation of EFAs/PUFAs and their con-
version to trans-fats that are harmful to the body [18].
Human diet was rich in ω-3 fatty acids in the early
humans. But with the progress in industrialization and
development of fast foods, the content of ω-3 fatty acids
in human diet dwindled, whereas that of ω-6 fatty acids
increased. The ratio of ω-3 to ω-6 fatty acids in the diet of
early humans was >1, whereas this ratio is now about 10:1
to 20–25:1. It is recommended that the ratio between ω-3
to ω-6 fatty acids in the diet should be about 1 or >1 and
preferably 2–3:1. This fall in the intake of ω-3 fatty acids,
especially EPA and DHA in the last 50 years is believed to
be responsible for the increasing incidence of atheroscle-
rosis, CHD, hypertension, metabolic syndrome X, obesity,
collagen vascular diseases and possibly, cancer. This is
supported by the observation that increasing dietary α-
linolenate/linoleate balance affected the ω-3/ω-6 ratio of
brain phospholipid acyl chains and produced changes in
general behavior as well as changes in sensitivities to
drugs known to affect behavior, influenced LTs formation
in polymorpho-nuclear leukocytes from AA and EPA and
release of histamine from mast cells that could alter the
severity of allergic and inflammatory responses. This
increase in ω-3 fatty acids also resulted in an increased
mean survival time of SHR-SP (spontaneously hyperten-
sive-stroke prone) rats by lowering blood pressure and
platelet aggregability, produced significant changes in
Na+-K+-ATPase activity, and altered collagen-induced
platelet aggregation and serotonin release in experimental
animals. These results suggest that enhanced intake of ω-
3 fatty acids is of significant benefit in various diseases.
Factors influencing the metabolism of EFAs
Dietary LA and ALA are metabolized by the same set of Δ6
and  Δ5  desaturases and elongases to their respective
metabolites (see Figure 1). These 2 fatty acids compete
with one another for the same set of enzymes and Δ6 and
Δ5 desaturases prefer ω-3 to ω-6. Oleic acid (OA, ω-9) that
is not an EFA is also metabolized by the same desaturases.
But, in view of the preference of these enzymes to LA and
ALA, under normal physiological conditions, the metabo-
lites of ω-9 are formed only in trivial amounts. Hence,
presence of significant amounts of 20:3 ω-9, a metabolite
of OA, in the cells and plasma indicates EFA deficiency
that is utilized to detect the presence of EFA deficiency in
patients, experimental animals and in vitro studies.
Of several factors that influence the activities of desatu-
rases and elongases [18], saturated fats, cholesterol, trans-
fatty acids, alcohol, adrenaline, and glucocorticoids
inhibit Δ6 and Δ5 desaturases. Pyridoxine, zinc, and mag-
nesium are necessary co-factors for normal Δ6 desaturase
activity. Insulin activates Δ6 desaturase whereas diabetics
have reduced Δ6 desaturase activity. The activity of Δ6
desaturase falls with age. Oncogenic viruses and radiation
inhibit  Δ6 desaturase. Total fasting, protein deficiency,
glucose rich diets reduce the activity of Δ6 desaturase. A
fat- free diet and partial caloric restriction enhances Δ6
desaturase. Activities of Δ6  and  Δ5  desaturases are
decreased in diabetes mellitus, hypertension, hyperlipi-
demia, and metabolic syndrome X. Trans-fats, saturated
fatty acids, and cholesterol interfere with EFA metabolism
and promote inflammation, atherosclerosis and coronaryLipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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heart disease (CHD) [18]. This implies that trans-fats, sat-
urated fats, and cholesterol have pro-inflammatory
actions whereas EFAs and PUFAs possess anti-inflamma-
tory properties. This explains why trans-fats, saturated
fats, and cholesterol are pro-atherogenic, whereas EFAs/
PUFAs, especially ω-3 fatty acids are anti-atherogenic. The
ability of trans-fats, saturated fats, and cholesterol to inter-
fere with the formation of AA, EPA, and DHA from dietary
LA and ALA could lead to decreased formation of LXs,
resolvins, PGI2 (prostacyclin), PGI3, and other beneficial
eicosanoids that prevent platelet aggregation, leukocyte
chemotaxis and activation. LXs and resolvins decrease the
formation of pro-inflammatory cytokines, and produce
vasodilatation, events that prevent or arrest atheroslcero-
sis. In contrast, trans-fats, saturated fats, and cholesterol
may directly activate leukocytes, induce the generation of
free radicals and enhance the production and release of
pro-inflammatory cytokines that facilitate atherosclerosis
[18]. Trans-fats, saturated fats, and cholesterol directly
activate leukocytes and macrophages to induce them to
produce free radicals and pro-inflammatory cytokines:
IL-6, TNF-α, IL-1, IL-2, and MIF (macrophage migration
inhibitory factor). This action of trans-fats, saturated fats,
and cholesterol is in addition to their ability to suppress
metabolism of EFAs to their respective long-chain metab-
olites. It is possible that trans-fats, saturated fats, and cho-
lesterol may also have the ability to inhibit the formation
of LXs, resolvins, PGI2, and PGI3. These studies suggest
that EFAs, especially EPA and DHA are cytoprotective to
endothelial cells, whereas trans-fats, saturated fats, and
cholesterol produce endothelial dysfunction. AA, EPA,
and DHA augment nitric oxide generation from endothe-
lial cells [18] and thus help in the prevention of endothe-
lial dysfunction. In contrast, trans-fats, saturated fats, and
cholesterol produce endothelial dysfunction and thus,
inhibit eNO production. Furthermore, NO quenches
superoxide anion and thus, prevents the cytotoxic action
of superoxide anion and protects endothelial cells from
free radical-induced damage. This implies that for
endothelial cells to be healthy they need adequate
amounts of AA, EPA, and DHA so that they can generate
physiological amounts of eNO not only to prevent patho-
logical platelet aggregation and atherosclerosis but also to
protect themselves from the cytotoxic actions of free radi-
cals.
Furthermore, NO reacts with PUFAs to yield their respec-
tive nitroalkene derivatives that can be detected in plasma.
These nitroalkene derivatives, termed as nitrolipids, pro-
duce vascular relaxation, inhibit neutrophil degranulation
and superoxide formation, and inhibit platelet activation,
and show anti-atherosclerotic properties [18]. Thus, there
appears to be a close interaction between EFAs and their
products and trans-fats, saturated fats, and cholesterol
with regard to the ability of endothelial cells to produce
PGI2, PGI3, NO, and other anti-atheroslcerotic and bene-
ficial molecules.
Actions of PUFAs that qualify them to be the 
endogenous HMG-CoA reductase and ACE 
enzyme inhibitors, anti-arrhythmic, anti-
hypertensive, anti-atherosclerotic, anti-
inflammatory, cytoprotective, and 
cardioprotective molecules
Action on HMG-CoA reductase
PUFAs are potent inhibitors of HMG-CoA reductase
enzyme and similar to statins are useful in the treatment
of hyperlipidemias [28-33]. Statins enhance plasma AA
levels and decrease the ratio of EPA to AA significantly
[29,30], and enhance the formation of prostacyclin
(PGI2) [32]. In fact, statins and PUFAs have many overlap
actions such as inhibition of IL-6 and TNF-α production
and NF-κB activation, increasing the synthesis of endothe-
lial nitric oxide (eNO); and both are anti-inflammatory in
nature [18,33-37]. In addition, a close interaction exists
between NO and COX enzymes attesting to the fact that
statins, PUFAs, and NO have positive and negative influ-
ences among themselves [38]. Both statins and PUFAs are
useful in atherosclerosis, coronary heart disease, oste-
oporosis, stroke, Alzheimer's disease, and inflammatory
conditions such as lupus [18,39-52]. These evidences sug-
gest that PUFAs mediate many, if not all, actions of statins
[33] and this could be one mechanism by which they
lower cholesterol levels. Recent studies revealed that stat-
ins augment concentrations of LXs in the heart [53,54]
lending support to this concept. Furthermore, when a
combination of statins and PUFAs are given together a
synergistic beneficial effect was seen in patients with com-
bined hyperlipemia [55-58]. But statins cannot be given
during pregnancy, whereas PUFAs have been recom-
mended during pregnancy, lactation and infancy to
improve brain growth and development, and cognitive
function [18-21], [59-67], though some studies did not
show improvement in cognition [68,69]. Nevertheless,
these studies reported that supplementation of PUFAs to
pregnant and lactating women and infants is safe and
without any side effects.
PUFAs modulate renin formation, ACE activity and 
endothelial nitric oxide generation
Angiotensin converting enzyme (ACE) inhibitors are use-
ful to lower blood pressure [11]. Renin, a proteolytic
enzyme, is produced and stored in the granules of the jux-
taglomerular cells in the kidney. Renin acts on angi-
otensinogen (a circulating α2 globulin made in the liver)
to form the decapeptide angiotensin-I (Ang-I). Ang-I is
transformed by ACE to angiotensin-II (Ang-II). Ang-II
controls blood pressure and regulates body fluid volume
by modulating renin-angiotensin-aldosterone system.Lipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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ACE is present in the uterus, placenta, vascular tissue,
heart, brain, adrenal cortex and kidney, leukocytes, alveo-
lar macrophages, peripheral monocytes, neuronal cells
and epididymal cells [70]. Angiotensin receptors are AT1
and AT2. AT1 exists as two subtypes α and β. Actions of
Ang-II are mediated by the AT1 receptor. Angiotensinases,
present in several tissues, destroy Ang-II (half-life approx-
imately 1 minute), while the half-life of renin is about 10
to 20 minutes. In addition to circulating renin-angi-
otensin, many tissues have a local renin-angiotensin sys-
tem and thus, have the ability to produce Ang-II. Locally
generated Ang-II is involved in the modulation of growth
and function of many tissues including vascular smooth
muscle.
Linseed oil (which contains approximately: 19% oleic
acid, 24% LA, and 47% ALA) fed experimental animals
showed significantly lower renal venous renin secretion
rates relative to the saturated fat-fed control group. Die-
tary enrichment with 20 energy % PUFA lowered renin
secretion by a prostaglandin-independent mechanism
that might have contributed to the lower blood pressures
observed compared with the saturated fat-fed control
group [71]. Dietary supplementation with 3 gm/day of LA
and 32 mg/day of GLA to pregnant and non-pregnant sub-
jects showed that the diastolic pressor response to angi-
otensin-II was significantly less in the pregnant subjects
compared to the non-pregnant subjects, suggesting that
PUFAs modulate vascular tissue responses to angiotensin-
II. This decreased response to angiotensin-II could be due
to increased formation of PGE1 and PGI2 in fatty acid sup-
plemented pregnant subjects [72,73]. In a model of
hypertension induced by continuous infusion of angi-
otensin-II in the rat, subcutaneous administration of LA
and EPA and DHA were found to be equally potent in
reducing, by half, the rise in systolic blood pressure
induced by angiotensin-II and these anti-hypertensive
effects were not accompanied by any changes in the renal
synthesis of PGI2 or PGE2. Furthermore, indomethacin, a
potent inhibitor of PGI2 but not of PGE2 synthesis could
only partially neutralize the anti-hypertensive effects of LA
and EPA/DHA, emphasizing that the anti-hypertensive
effects are independent of the PG system [74]. This idea is
reinforced by the observation that LA and AA inhibit
renin, and thus, the overall activity of the renin-angi-
otensin-aldosterone cascade could be modified by altera-
tions of plasma fatty acid concentrations [75,76], though
in two-kidney, one-dip hypertensive animals, pretreat-
ment with indomethacin did not alter hypotensive
response to LA despite the fact that LA infusion lowered
blood pressure in high renin but not in low renin states
and the reduction in blood pressure was not related to
inhibition circulating renin or to alterations of endog-
enous PG biosynthesis [77]. These evidences suggest that
PUFAs have modulatory influence on renin secretion and
action and yet times independent of both renin secretion
and PG formation. Since the anti-hypertensive actions of
PUFAs seem to be independent of formation of PGs, it is
likely that fatty acids themselves are able to bring about
this action and/or converted to form lipoxins, resolvins
and protectins that have anti-inflammatory action and
also possibly, anti-hypertensive action. But this proposal
needs to be verified and confirmed. Yet another possibil-
ity is that the PUFAs supplemented are incorporated into
the cell membrane phospholipid fraction that is able to
enhance the synthesis of eNO that is a potent vasodilator
and platelet anti-aggregator.
Previously, I showed that PUFAs inhibit leukocyte ACE
activity [78]. Of all the fatty acids tested, EPA was the most
effective (EPA > ALA > DHA > GLA > LA > AA), whereas
AA was the least effective when their ability to inhibit
purified ACE activity was tested. DHA and EPA were the
most effective fatty acids in inhibiting the leukocyte ACE
activity (EPA > DHA > ALA = AA > LA > GLA). On the
other hand, PGs (PGE1, PGE2, PGI2 and PGF2α), and free
radicals: superoxide anion, hydrogen peroxide, and
hydroxyl radical showed marginal (~20%) inhibitory
action on ACE activity. In contrast, NO (nitric oxide)
showed powerful inhibitory action on ACE activity [78],
whereas PUFAs enhanced endothelial nitric oxide (eNO)
generation [36,47,79]. The effects of PUFAs on ACE activ-
ity, and NO generation and the inability of free radicals
and PGs to suppress ACE activity are interesting since
there is a close interaction between platelets, leukocytes
and endothelial cells that may have relevance to their
involvement in CVD (cardiovascular diseases). For
instance, under normal conditions, endothelial cells pro-
duce adequate amounts of PGE1 from DGLA; PGI2 from
AA; LXs and resolvins from AA, EPA and DHA; and NO
from L-arginine such that the pro-inflammatory and pro-
atherosclerotic events such as hemodynamic forces,
hyperlipidemia, hypertension, smoking are successfully
abrogated. These factors induce the expression of pro-
inflammatory genes that initiate and accelerate athero-
sclerosis at the points of shear stress, enhance infiltration
of intima by leukocytes and macrophages, cause low-level
activation of NF-κB and elevated expression of VCAM-1
and ICAM-1, IL-1, IL-6, MCP-1, as well as antioxidant
genes glutathione peroxidase and glutathione-S- trans-
ferase 2, and pro-inflammatory eicosanoids such as TXA2,
PGE2, PGF2α, LTs, and other PGs, TXs, and LTs, and
increased production and release of free radicals and UCP
(uncoupling proteins) expression occurs in endothelial
cells, platelets, and leukocytes in atherosclerosis-suscepti-
ble regions, and endothelial cells themselves may show
changes in cell shape and proliferation. These events can
be prevented and atherosclerosis process and the onset of
CVD can be arrested if the production of PGE1, PGI2,
PGI3, LXs, resolvins, NO, and anti-inflammatoryLipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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cytokines such as IL-4, IL-10, TGF-β by endothelial cells is
adequate, provided there are adequate stores of respective
precursors of various PUFAs and L-arginine and their
respective enzymes. This suggests that under physiological
conditions a delicate balance is maintained between pro-
and anti-inflammatory and pro and anti-atherosclerotic
factors and when this balance is tilted more towards the
former atherosclerosis and CVD occurs (reviewed in [80]).
In addition, these results suggest that when tissue concen-
trations of PUFAs are low, the activity of ACE will be high
resulting in increased formation of angiotensin-II and a
simultaneous decrease in eNO. In this context, it is impor-
tant to note that transgenic rats overexpressing human
renin and angiotensinogen genes (dTGR) develop hyper-
tension, inflammation, and renal failure, and showed spe-
cific renal P450-dependent AA metabolism changes that
led to decreased formation epoxy-eicosatrienoic acids
(5,6-, 8,9-, 11,12- and 14,15-EETs) and hydroxyeicosa-
tetraenoic acids (19- and 20-HETEs). Both EETs and
HETEs inhibit IL-6 and TNF-α-induced activation of NF-
κB and prevent vascular inflammation [81], suggesting
that AA and other PUFAs not only regulate ACE activity
and Ang-II levels in the tissues but also possess anti-
inflammatory properties by generating anti-inflammatory
metabolites.
AA, EPA, and DHA are converted in the presence of aspirin
to epi-lipoxins, lipoxins, and resolvins that possess potent
anti-inflammatory actions (reviewed in [18]). Epi-lipox-
ins enhance the formation of eNO [18,21,22]. NO blocks
the interaction between leukocytes and the vascular
endothelium and also stimulates the formation of PGI2, a
potent vasodilator and platelet anti-aggregator, from AA
[82]. This suggests that the beneficial actions of aspirin
could be attributed not only to its ability to enhance the
formation of PGI2 and suppress the synthesis of TXA2 but
also to the formation of epi-lipoxins and eNO [20,21,82].
Thus, PUFAs regulate renin formation and action, inhibit
angiotensin-II formation by its action on ACE activity,
enhance eNO formation, and form precursors to benefi-
cial biologically active molecules such as PGE1  (from
DGLA), PGI2 (from AA), PGI3 (from EPA), lipoxins (from
AA, EPA, and DHA), resolvins (from AA, EPA and DHA),
protectins (from DHA), and 5,6-, 8,9-, 11,12- and 14,15-
EETs and hydroxyeicosa-tetraenoic acids (19- and 20-
HETEs) (from AA), and thus serve as endogenous regula-
tors of vascular tone, platelet aggregation, and blood pres-
sure.
Effects on platelets and other hemostatic indices
Aspirin is effective in the prevention and treatment of
acute myocardial infarction (AMI) and in the secondary
prevention of CVD [83], though the efficacy of aspirin in
women is not certain [16]. One of the important constit-
uents of the "polypill" is aspirin (75 mg). Studies revealed
that low dose aspirin not only reduced risk of heart dis-
ease, but also reduced the incidence of lung, colon, and
breast cancer [84]. Aspirin inhibits nuclear factor NF-κB
transcription, blocks prostaglandin (PG) and thrombox-
ane (TX) synthesis (TXA > PGI2). Aspirin does not inhibit
the production of proinflammatory mediators such as
leukotrienes (LTs). Although blockage of PGs and TXs
accounts for many of aspirin's pharmacologic properties,
recent studies revealed that aspirin evokes the formation
of 15-epi-LXA4 by the acetylated PGHS-2 [prostaglandin
G/H synthase (cyclooxygenase)] and 5-lipoxygenase
enzymes as a result of endothelial cell-leukocyte interac-
tions [85]. LXA4 inhibits polymorphonuclear leukocyte
transmigration, modulate adhesion to endothelial cells,
and inhibit chemotaxis of PMN and eosinophils. Thus,
many beneficial actions of aspirin could be attributed to
the formation of LXA4. In this context, it is noteworthy
that AA, EPA, and DHA when used in appropriate concen-
trations and ratio can reproduce many of the beneficial
actions of aspirin.
Both EPA and DHA, when given orally, are rapidly incor-
porated into platelets and compete with AA for the 2-acyl
position of membrane phospholipid and as substrate for
the cyclo-oxygenase (CO) and lipoxygenase (LO)
enzymes. As a result, when stimulated, such platelets pro-
duce less amounts of TXA2 and more of TXA3 that is less
potent in inducing platelet aggregation and thrombosis
[86]. Increased intake of fish oil, a rich source of EPA and
DHA, produces a lower platelet count, less platelet aggre-
gation, a longer bleeding time, higher urinary PGI2 metab-
olites, and lower concentrations of thromboxane
metabolites compared to those who were on Western diet
[87,88], effects that are similar to those of low-dose aspi-
rin and qualify ω-3 EPA and DHA to be termed as an
"endogenous aspirin". In general, though EPA and DHA
do not have a very significant effect on blood lipids
(except to lower plasma triglycerides and VLDL with no
significant action on HDL-C levels), fibrinolysis and on
the activity of plasminogen activity inhibitor-type-1 (PAI-
1), still are effective in preventing overall mortality from
CVD [18,21,80,89-94].
It is believed that production of pro-inflammatory eicosa-
noids from AA and/or decreased synthesis of anti-inflam-
matory and beneficial eicosanoids from EPA/DHA could
predispose an individual to cardiovascular risk and stroke.
Thus, it is thought that products of AA such as TXA2, PGEs,
PGFαs, and LTs contribute or initiate the process of athero-
sclerosis in coronary arteries and cause CHD. In contrast,
it has been proposed that beneficial products or less
harmful products formed from EPA and DHA are less
likely to cause atherosclerosis and CHD or even regress
atheroma and prevent CHD. Although this is an attractiveLipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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hypothesis, hard data in support of this proposal are not
forthcoming. In this context, it should be noted that not
all products of AA are harmful. For instance, PGI2 formed
from AA is a potent vasodilator and platelet anti-aggrega-
tor and prevents atherosclerosis and has anti-arrhythmic
action [95].
Similarly, DGLA, another ω-6 fatty acid that is the precur-
sor of AA, gives rise to PGE1, which is a vasodilator, plate-
let anti-aggregator and anti-arrhythmic molecule [96,97].
These data emphasize the complexities involved in mak-
ing generalizations about ascribing negative role to ω-6
fatty acids and their products in CVD. Furthermore, AA
forms precursor to LXs and resolvins (See Figure 1) that
have beneficial actions in resolving inflammation. In
addition, Harris et al [98] noted that pooling of data from
case-control or prospective cohort studies showed that
none of the individual fatty acids computed across data-
sets were significantly different between cases and con-
trols. EPA was 8.2% lower (p = 0.06), DHA was 8% lower
in cases compared with controls, whereas DPA (docosap-
entaenoic acid) was virtually identical in both controls
and CHD patients. In contrast and contrary to expecta-
tions, AA was 8.5% lower in cases compared to controls.
The unexpected finding that AA concentrations were
lower in patients with CHD suggests that it is the defi-
ciency of AA rather than its excess that predisposes to
CHD events. In addition, data from the Health Profes-
sionals' Follow-up Study [99] revealed that while there is
an inverse relationship between ω-3 fatty acid intake and
future risk for CHD, higher intakes of ω-6 fatty acids did
not diminish the beneficial effects of ω-3 fatty acids sug-
gesting that the absolute intakes of the ω-3 fatty acids are
more important than the ratio between ω-3 fatty acids and
ω-6 fatty acids. In this context, the interaction(s) between
ω-3 and ω-6 fatty acids are significant.
Interaction(s) between ω-3 and ω-6 fatty acids and its 
relevance to CHD/CVD
In a case control study of new angina pectoris and first
acute myocardial infarction, a progressive inverse relation
between adipose tissue LA and the estimated relative risk
of CHD was noted [100]. Wood, et al [101] observed that
low concentrations of DGLA in adipose tissue showed a
more significant relation to new CHD than did LA. In an
extension of this study, it was noted that there is a progres-
sive inverse relations between adipose LA and platelet-
membrane EPA and the estimated relative risk of angina
pectoris. These relations were statistically independent of
each other and traditional CHD risk factors [100-102].
Luostarinen, et al [103] noted that the percentage of pal-
mitic acid and LA were significantly higher and the per-
centage of AA and of all the other major PUFAs, both ω-3
and ω-6, was significantly lower in the total phospholipid
fraction of human coronary arteries of those who had sud-
den cardiac death due to CHD. Felton, et al [104] reported
that the concentrations of all fatty acids were increased at
the edge of disrupted plaques compared with the center,
but as a proportion of total fatty acids, ω-6 were lower.
These results suggest that ω-6 fatty acids have a significant
role in CHD and it is likely that some of the inconsistent
results obtained in some studies with EPA and DHA could
be attributed to inadequate provision or utilization of ω-
6 fatty acids, DGLA and AA. It is possible that there is a
close interaction between ω-3 and ω-6 fatty acids, which
could influence one's susceptibility or resistance to CHD.
In this context, it is interesting to note that EPA/DHA
readily get incorporated into the atheromatous plaque,
and patients treated with fish oil had more thick fibrous
caps and no signs of inflammation compared with
plaques in patients in the control and sunflower oil
groups. Furthermore, the number of macrophages in
plaques from patients receiving fish oil was lower than in
the other two groups, suggesting that atherosclerotic
plaques readily incorporate ω-3 PUFAs from fish-oil sup-
plementation, inducing changes that can enhance stabil-
ity of atherosclerotic plaques [105].
Studies revealed that ω-3 and ω-6 fatty acids interact with
each other in such a way that one potentiates the metabo-
lism of the other. For instance, in perfused vascular tissue,
DGLA increases the conversion of EPA to PGI3, a potent
vasodilator and platelet anti-aggregator [106], whereas AA
augmented the conversion of EPA to PGI3 in the tissues
[107-109]. EPA inhibits the activity of the enzyme Δ5
desaturase that results in an increase in the concentrations
of DGLA in the tissues (especially in the endothelial cells).
This increase in tissue levels of DGLA could enhance the
formation of PGE1, a vasodilator and platelet anti-aggre-
gator (see Figure 1). Thus, EPA can indirectly enhance the
formation of PGE1. Furthermore, even the beneficial
action of statins (HMG-CoA reductase inhibitors) and gli-
tazones (PPARs agonists) seem to be mediated by EFAs
and their metabolites such as LXs, resolvins, and neuro-
protectins [28-33], [110-114], which are potent anti-
inflammatory molecules [18,21,115-117]. Studies did
suggest that ω-3 fatty acids decreased the levels of pro-
inflammatory cytokines, and enhance that of IL-10, an
anti-inflammatory cytokine [118-120]. This close interac-
tion between ω-3 and ω-6 fatty acids and their ability to
modify inflammatory markers, production of PGI2, PGE1,
PGI3, LXs, resolvins, neuroprotectins, NO, nitrolipids,
and the action of statins and glitazones on EFA metabo-
lism and NO explains the relationship between various
fatty acids and CHD and stroke (Figure 1).
PUFAs in renal function
One of the components suggested to be included in the
"polypill" is a thiazide, a diuretic and an anti-hypertensiveLipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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drug. If PUFAs are to be considered to function as an
endogenous "polypill", then they (PUFAs) should show
beneficial actions on renal function.
Healthy volunteers given EPA (3.9 gm) and DHA (2.4 gm)
per day for 6 weeks showed significant increase in renal
plasma flow, glomerular filtration rate, decrease in renal
vascular resistance, and an increase in excretion of PGE3
with no change in blood pressure and heart rate [121].
Diet rich in evening primrose oil (a rich source of GLA and
LA) and safflower oil decreased proteinuria, glomerular
sclerosis, and tubular abnormalities in diabetic rats, and
showed increased ratio of renal cortical production of 6-
keto-PGF1α (a metabolite of PGI2) to TXB2 with no signif-
icant changes in plasma lipid composition. In contrast,
fish oil feeding decreased plasma lipids and lowered 6-
keto-PGF1α/TXB2 ratio without any effect on renal disease
in diabetic rats [122]. Singer et al [123] observed that
spontaneously hypertensive rats had significantly lower
systolic blood pressure when fed fish oil (EPA and DHA),
evening primrose oil (a rich source of GLA), and fish oil +
evening primrose oil, suggesting that a combination of
GLA, EPA, and DHA produces optimal beneficial actions
with regard to renal indices and blood pressure. Vaskonen
et al [124] reported that fish oil prevented rise in blood
pressure induced by high-salt diet in stroke-prone sponta-
neously hypertensive rats. This beneficial effect on blood
pressure was associated with a decrease in TXB2 formation
by 75% and an increase in plasma and renal ω-3 fatty acid
content.
Furthermore, EPA/DHA suppressed mesangial cell prolif-
eration, arrested progression of IgA nephropathy, and
protected against cyclosporine-induced renal damage
[125-127]. These results suggest availability of optimal
amounts of GLA and EPA/DHA is necessary to reduce
blood pressure and preserve renal function in diabetic and
hypertensive rats. Studies performed with 5/6 renal abla-
tion rat model that developed hypertension, albuminuria,
and a decline in glomerular filtration rate had signifi-
cantly less glomerulosclerosis and dyslipidemia when
supplemented with fish oil and flax seed oil (rich in ALA)
compared with the control group at 10 and 20 wk post-
surgery [128,129]. Thus, PUFAs may show actions similar
to those observed with conventional, synthetic diuretics.
These beneficial actions of PUFAs can be attributed to the
formation of beneficial PGA, PGE3, PGI2, PGI3, and
recently identified resolvins and protectins and decrease
in the production of TXA2 and LTs [130]. It is interesting
that diuretic furosemide enhances endothelial synthesis
and release of bradykinin and related kinins that, in turn,
stimulates endothelial PGI2 formation via B2 kinin recep-
tor activation [131] and COX-2 derived PGs interact with
the renin-angiotensin system to regulate renal function
[132].
PUFAs and parasympathetic nervous system
Previous studies showed that multiple-blood pressure
lowering drugs have additive effects, which led Wald and
Law to suggest that a β-blocker need to be added to the
"polypill" composition. This is in addition to the presence
of a diuretic (such as a thiazide) and an ACE-inhibitor
[11]. Autonomic function is an important factor that reg-
ulates heart rate, blood pressure and cardiac rhythm.
Hence, it is expected that addition of β-blocker to the
composition of "polypill" will reduce sympathetic tone,
blood pressure and heart rate.
Autonomic function is assessed by the measurement of
heart rate variability (HRV) and the evaluation of barore-
flex sensitivity (BRS). HRV reflects the physiological levels
of tonic autonomic regulation, whereas BRS indicates the
capacity of reflex autonomic regulation. Both low HRV
and low BRS are associated with increased cardiovascular
risk. Vagal stimulation by a release of acetylcholine (ACh)
and adrenergic stimulation mediated by norepinephrine
and epinephrine regulate the autonomic function and
thus the variations in HRV and BRS. Several studies
revealed that ω-3 fatty acids reduce the risk of sudden
death by preventing life-threatening cardiac arrhythmias
and by significantly increasing HRV [133]. Furthermore, a
direct positive correlation was noted between the content
of DHA in cell membranes and HRV index suggesting an
anti-arrhythmic effect of ω-3 fatty acids [134]. Since
increased parasympathetic tone is responsible for increase
in ventricular fibrillation threshold and protects against
ventricular arrhythmias, it is likely that EPA/DHA supple-
mentation enhances parasympathetic tone. This is sup-
ported b the observation that EPA/DHA supplementation
increases hippocampal ACh levels, the principal neuro-
transmitter of parasympathetic nerves [135]. Hence, it is
likely that EPA/DHA supplementation increases the brain
ACh levels leading to an increase in the parasympathetic
tone and so an increase in HRV and protection from ven-
tricular arrhythmias. Similar to EPA/DHA, AA also aug-
ments ACh release [136,137], and thus, PUFAs enhance
parasympathetic tone resulting in an increase HRV and
prevention of ventricular arrhythmias.
Vagus nerve stimulation also inhibits TNF synthesis in
liver and ACh significantly attenuated the release of pro-
inflammatory cytokines: TNF-α, IL-16, IL-1β, and IL-18
but not anti-inflammatory cytokine IL-10 by stimulated
macrophages  in vitro and  in vivo [138-140]. Thus, one
mechanism by which PUFAs suppress inflammation
could be by augmenting the release of ACh and enhancing
the parasympathetic tone.
Since, normally a balance is maintained between para-
sympathetic and sympathetic tones, it is reasonable to
suggest that whenever parasympathetic tone (vagal tone)Lipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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is enhanced sympathetic tone is reduced (akin to blocking
of β-receptors as it occurs in instances of use of β-block-
ers). Thus, indirectly PUFAs may function like β-blockers.
Folic acid and PUFAs
Hyperhomocysteinemia is a risk factor for cardiovascular
diseases, and it may interact with hypertension and an
unfavorable cholesterol profile to alter the risk of CVD.
Hence, folic acid (0.8 mg/day) has been added as a com-
ponent of the "polypill". It is important to note that folic
acid increases concentrations of ω-3 PUFAs which could
reduce the risk of thrombosis and CVD [141-143]. It was
observed that some of the adverse effects induced by folic
acid deficiency could be overcome by supplementing with
ω-3 EPA and DHA [144], and in folic acid deficiency states
the plasma and brain concentrations of PUFAs are
decreased [145]. These results imply that some, if not all,
actions of folic acid are mediated by PUFAs.
Thus, PUFAs, when given in appropriate dose and combi-
nation (containing EPA, DHA and possibly, GLA, DGLA
and AA) show all the qualities of the suggested "polypill",
viz., aspirin-like action, inhibit the activities of HMG-CoA
and ACE enzymes, possess diuretic and anti-hypertensive
actions, and indirectly show β-blocker-like action. In
addition to these useful actions, PUFAs also have other
beneficial actions as described below.
PUFAs inhibit cholesteryl ester transfer protein (CETP) 
activity
HDL-cholesterol (high-density lipoprotein- cholesterol,
HDL-C) is an independent risk factor for CHD. Higher
plasma HDL-C is associated with a decreased incidence of
CHD [146] that led to the suggestion that therapeutic
strategies that raise HDL-C could be of benefit in prevent-
ing CHD by increasing the movement of cholesterol from
the periphery back to the liver (the so-called reverse cho-
lesterol transport or RCT pathway).
CETP is a hydrophobic plasma glycoprotein, mainly syn-
thesized in the liver, possessing the unique ability to facil-
itate the transfer of cholesteryl ester (CE). CETP circulates
in the blood, bound predominantly to HDL. CETP medi-
ates the transfer of cholesteryl esters from HDL to VLDL
and LDL in exchange for triglycerides and promotes the
transformation of HDL2 to HDL3, an action that could
promote reverse cholesterol transport. CETP inhibition
produces an increase in HDL by markedly delaying catab-
olism of apoA-I and A-II [147], an action that increases
reverse cholesterol transport. These actions suggest that
CETP inhibition could prevent atherosclerosis and pre-
vent CHD [148-150].
In healthy, normolipidemic men, it was observed that
lipid-lowering diet rich in monounsaturated fatty acid
(oleic acid) decreased CETP concentrations to a signifi-
cant degree [151]. In HepG2 cells, 0.5 mM of AA, EPA,
and DHA reduced the levels of CETP mRNA by more than
50% of the control levels with a corresponding significant
decrease in the CETP mass [152]. A significant negative
correlation was found between plasma CETP activity and
monounsaturated fatty acid content of plasma phosphol-
ipids or free PUFAs including ω-3 fatty acids, suggesting
that PUFAs suppress CETP activity [153].
Torcetrapib, a small molecule inhibitor of CETP, is very
effective at raising HDL-C and apolipoprotein A-I and
decreasing levels of LDL-C and apolipoprotein-B-100 and
also showed favourable effects on increasing the size of
HDL-and LDL particles. In patients with familial hyperc-
holesterolemia, torcetrapib with atorvastatin as compared
with atorvastatin alone did not result in reduction of pro-
gression of atheroslcerosis as measured by carotid arterial-
wall thickness despite a significant increase in HDL-C lev-
els and decrease in levels of LDL-C and triglycerides. In
fact, it was observed that administration of torcetrapib
with atorvastatin was associated with progression of
atherosclerosis [154], and an increase in blood pressure
with no significant decrease in the progression of coro-
nary atherosclerosis [155]. These results with torcetrapib +
atorvastatin suggest that simultaneous inhibition of CETP
and HMG-CoA reductase enzyme leads to an elevation of
plasma HDL-C, and decrease in LDL-C and triglycerides
and cholesterol but it does not arrest progression of
atherosclerosis. In contrast, PUFAs, especially ω-EPA and
DHA, not only inhibit CETP and HMG-CoA reductase
enzyme, lower plasma triglycerides, cholesterol, and LDL-
C with little or no change in HDL-C but also are effective
in arresting atherosclerosis and preventing CHD [156-
165]. In contrast to the results with torcetrapib + atorvas-
tatin, Yokoyama et al [166] reported that a combination
of ethyl EPA + 10 mg of pravstatin or 5 mg of simvastatin
prevented major coronary events and especially non-fatal
coronary events in Japanese hypercholesterolemic
patients with a mean period of follow up of 4.6 years. It is
interesting to note that the benefits were in addition to
statin treatment, and fish oil was found to be safe and well
tolerated. These results once again confirm that EPA and
DHA are of benefit in the prevention and treatment of car-
diovascular diseases. Thus, PUFAs appear to be superior to
CETP and statins in the prevention of CVD despite the fact
that they do not necessarily increase plasma HDL-C levels.
EPA, DHA, and PGI2 function as endogenous anti-
arrhythmic molecules
There is reasonable evidence to suggest that EPA/DHA and
PGI2  have anti-arrhythmogenic effects. Various PUFAs
and PGs are present in the heart including SA (sinoatrial)
node [167,168]. I showed that PGE1, PGE2, PGI2, and
TXB2 modify contractions of isolated rat cardiac muscleLipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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cells and increased the amount of 45Ca2+ exchanged by
non-beating cells [169]. These results led to the suggestion
that PGI2 could be an endogenous anti-arrhythmic mole-
cule [170]. It was reported that PUFAs increased the elec-
trical threshold for the induction of ventricular fibrillation
that could reduce the risk of developing malignant cardiac
arrhythmias. Mitochondrial dysfunction induced by EFA
deficiency could be eliminated by the presence of normal
levels of the essential fatty acids in the ω-3-enriched mito-
chondrial membrane phospholipids [171] that may
account for the ability of EPA/DHA to decrease cardiac
arrhythmias during myocardial ischemia. The recovery of
mitochondrial energy metabolism and myocardial pump
function during reperfusion is significantly better in ω-3
PUFA-enriched hearts, suggesting that EPA and DHA limit
myocardial injury during ischemia and reperfusion [172].
EPA and DHA (at 2–10 microM) reduced the contraction
rate of spontaneously beating, isolated, neonatal rat car-
diac myocytes [173] without a significant change in the
amplitude of the contractions. Both CO- and LO-inhibi-
tors and antioxidants did not alter the effect of the fatty
acids. The inhibitory effect of EPA and DHA on the con-
traction rate was similar to that produced by the class I
antiarrhythmic drugs. It was also reported that lysophos-
phatidylcholine (LPC)- or acylcarnitine-induced arrhyth-
mias were completely blocked by EPA, DHA, ALA, AA,
and LA by inhibiting the electrical automaticity/excitabil-
ity of the cardiac myocytes. Studies using whole-cell
patch-clamp technique in cultured neonatal rat ventricu-
lar myocytes revealed that EPA, DHA, and to a limited
extent AA can produce a concentration dependent sup-
pression of ventricular, voltage-activated Na+ currents that
may explain their anti-arrhythmic actions in vitro and in
vivo [174-176].
PUFAs modulate telomere and telomerase activity
Telomere, the genetic segment that appears at the end of
the chromosomes, has the special property of protecting
these ends. Telomerase is the enzyme that adds telomere
repeats to the ends of the chromosomes with the use of a
dedicated RNA template. Inactivation of telomerase leads
to telomere shortening and eventual senescence of the
cells. Telomerase consists of two principal subunits: tel-
omerase reverse transcriptase (TERT), the protein catalytic
subunit, and the telomerase RNA component (TERC). Pri-
mary cells when grown in vitro, lack sufficient TERT to
maintain telomeres and hence, telomeres shorten progres-
sively with each cell division. This eventually results in
shorter telomere that loses its ability to protect the ends of
chromosomes and is therefore recognized by the cell's
DNA repair machinery as damaged DNA. The loss of tel-
omere results in cellular senescence since cell can no
longer divide and replicate itself. In contrast, overexpres-
sion of TERT prevents telomere attrition and enables cells
to proliferate indefinitely, a character of cancer cells. Thus,
telomere and telomerase are central to several diseases
such as cancer, aging, atherosclerosis, CHD, type 2 diabe-
tes, hypertension, and to the biology of stem cells.
Recent reports suggested that leukocyte telomere length is
a predictor of future CHD in middle-aged, high-risk men,
whereas 10 mg of pravastatin, a HMG-CoA reductase
inhibitor, substantially abrogated shortening of the tel-
omere length in high-risk subjects [177-179], suggesting
that patients with CHD have senescent endothelial cells.
Telomere shortening has been reported in patients with
type 2 diabetes mellitus, hypertension, and insulin resist-
ance [180-184]. Diabetes mellitus, hypertension, insulin
resistance, and CHD are not only low-grade systemic
inflammatory conditions in which plasma levels of lipid
peroxides, IL-6, and TNF-α are increased and eNO and
concentrations of anti-oxidants are decreased, but also
show shorter leukocyte telomere length compared to con-
trols. NO activates telomerase [185] and delays endothe-
lial cell senescence [186], whereas asymmetrical dimethyl
arginine, an inhibitor of NO synthesis, enhances endothe-
lial cell senescence [187,188]. It was reported that stable
expression of hTERT (human telomerase reverse tran-
scriptase) enhances production of eNO and NO activity
and renders endothelial cells to show younger phenotype
[189,190], whereas NO activates telomerase and delays
endothelial cell senescence. These results imply that NO
prevents whereas reactive oxygen species induce telomere
shortening.
In contrast, tumor cells express increased telomerase activ-
ity. Tumor cells have relatively higher content of anti-oxi-
dants and reduced concentrations of lipid peroxides due
to PUFA deficiency. It is known that ω-3 PUFAs are of ben-
efit in type 2 diabetes, hypertension, and hypertriglyceri-
demia and prevent CHD, in part, by enhancing NO
generation from endothelial cells and decreasing insulin
resistance [191]. Tumor cells undergo apoptosis on expo-
sure to ω-3 PUFAs (especially in response to EPA, DHA,
and GLA) due to increase in intracellular free radical gen-
eration and formation of lipid peroxides. Since, NO and
lipid peroxides modify telomerase activity, it is likely that
PUFAs enhance or decrease activity of TERT in endothelial
cells and tumor cells respectively. This is supported by the
observation that EPA and DHA inhibit hTERT activity in
human colorectal adenocarcinoma cells [192,193]. Thus,
PUFAs can prevent, reverse or arrest atherosclerosis and
CHD by their ability to enhance eNO synthesis that, in
turn, augments hTERT activity and prevents endothelial
senescence.
Conclusion
It is evident from the preceding discussion that PUFAs,
especially an optimal combination of EPA, DHA and pos-Lipids in Health and Disease 2008, 7:37 http://www.lipidworld.com/content/7/1/37
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sibly, GLA, DGLA and AA show most the qualities of the
suggested "polypill", viz., aspirin-like action, inhibition of
HMG-CoA and ACE enzymes, and possess diuretic, anti-
hypertensive, and β-blocker-like actions (see Table 1 for a
summary of actions). PUFAs are naturally occurring
endogenous substances, present in almost all tissues and
are essential components of all mammalian cells and have
been shown to be relatively safe when administered to dif-
ferent types of patients for long periods of time (from few
months to few years). This is evident from the fact that
Eskimos consume large amounts of marine fish that are
rich in ω-3 fatty EPA and DHA and are not known to suffer
from any significant side effects. Nevertheless, possible
side effects due to long-term feeding of PUFAs need to be
studied. One concern that is generally expressed about
PUFAs is that their increased intake may enhance lipid
peroxidation, and that these oxidized products could be
harmful to tissues. But, it was reported that increased
intake of EPA/DHA, in fact, reduces in vivo lipid peroxida-
tion and oxidative stress in humans [194-196]. Further-
more, peripheral leukocytes, which are major mediators
of inflammation, are capable of de novo production of cat-
echolamines that enhance the inflammatory response
[197]; whereas vagal parasympathetic signaling sup-
presses inflammation through cholinergic receptors on
these cells [138]. This suggests that sympathetic and para-
sympathetic pathways and immune system cross talk with
each other during inflammation. PUFAs, especially ω-3
fatty acids enhance acetylcholine levels [135-137] and
increase HRV [133,134] due to their ability to augment
parasympathetic tone and thus, indirectly function as
endogenous suppressors of sympathetic nervous system
and thus, of β-receptor function. This is especially so since
under normal conditions a balance is maintained
between sympathetic and parasympathetic systems and
pro- and anti-inflammatory pathways. These evidences
imply that PUFAs function as endogenous enhancers of
parasympathetic tone, suppress inflammatory events; and
inhibit sympathetic over activity, and block β-receptor
action.
In view of these beneficial actions (see Table 2 for a sum-
mary of their actions), ω-3 and ω-6 fatty acids can be given
for the prevention of CVD. Since PUFAs can be given to
pregnant women and lactating mothers, and children, it is
suggested that a combined ω-6 and ω-3 pill could be given
from childhood. Furthermore, several studies suggested
that PUFAs, especially ω-3 fatty acids, are useful in the pre-
vention and treatment of Alzheimer' disease, schizophre-
nia, and depression [198-209], suggesting that PUFAs
have a much wider benefit compared to the "polypill". It
may also be mentioned here that for their physiological/
beneficial action(s) PUFAs need many co-factors such as
folic acid, vitamin B12, vitamin B6, vitamin C, tetrahydro-
biopterin (H4B), zinc, magnesium, calcium, L-arginine,
and small amounts of selenium and vitamin E [18].
Hence, it is essential that these co-factors should also be
provided in adequate amounts to bring about the benefi-
cial action of ω-6 and ω-3 PUFAs. Since statins, glitazones,
several anti-hypertensive and anti-arrhythmic drugs seem
to be mediate their actions by modulating EFA/PUFA
metabolism, it is possible that sub-clinical deficiency or
altered metabolism of EFAs may subvert their actions/
benefits. Hence, it is prudent to provide a combination of
ω-6 and ω-3 PUFAs and their co-factors along with statins,
glitazones, and other drugs in the treatment of CVD.
Yokoyama et al [166] showed that long-term use of ethyl
EPA (1800 mg/day) produced a significant reduction in
non-fatal coronary events in patients with dyslipidemia
compared to control. This risk reduction occurred after 2.5
years of use of ethyl EPA (mean follow up period was 4.6
years) even when PUFAs were added in addition to statin
treatment lending support to the concept that ω-3 and ω-
6 PUFAs can be combined with other cardiovascular drugs
in the prevention and treatment of cardiovascular dis-
eases.
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Table 1: Possible cumulative impact of four secondary prevention treatments in the prevention of cardiovascular diseases.
Drug therapy Relative-risk reduction 2-year event ratio
None - 8%
Aspirin 25% 6%
B-blockers 25% 4.5%
Lipid lowering (by 1–5 mmol) 30% 3.0%
ACE inhibitors 25% 2.3%
Cumulative relative reduction if all four drugs are used is about 75% [see ref. [91]].
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